Lexeo Therapeutics, Inc Common Stock

Yahoo Finance • 17 days ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 202... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Lexeo Therapeutics, Inc. is placed sixteenth on our list. TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target... Full story

Yahoo Finance • 4 months ago

Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks

As December draws to a close and Christmas arrives, investors are pausing to look back and assess a year that never followed a simple script. Policy uncertainty lingered, and trade headlines remained unpredictable as President Trump contin... Full story

Yahoo Finance • 5 months ago

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HE... Full story

Yahoo Finance • 5 months ago

Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential

Lexeo Therapeutics (NASDAQ:LXEO) is one of billionaire Daniel Sundheim’s stock picks with huge upside potential. On October 21, Leerink’s Mani Foroohar lowered the price target on Lexeo Therapeutics (NASDAQ:LXEO) from $20 to $18 but mainta... Full story

Yahoo Finance • 6 months ago

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of... Full story

Yahoo Finance • 6 months ago

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its u... Full story

Yahoo Finance • 6 months ago

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it ha... Full story

Yahoo Finance • 6 months ago

Lexeo climbs after regulatory update on Friedreich ataxia drug

[FDA headquarters in Washington DC.] JHVEPhoto Lexeo Therapeutics (NASDAQ:LXEO [https://seekingalpha.com/symbol/LXEO]) added ~29% in the premarket on Tuesday after the company announced that the U.S. FDA has defined a pathway that will al... Full story

Yahoo Finance • 6 months ago

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data show sustained or dee... Full story

Yahoo Finance • 8 months ago

Lexeo Therapeutics stock price target lowered to $9 at H.C. Wainwright

Investing.com - H.C. Wainwright lowered its price target on Lexeo Therapeutics (NASDAQ:LXEO) to $9.00 from $15.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $4.79, LXEO appears undervalued according to Inv... Full story

Yahoo Finance • 8 months ago

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, M... Full story

Yahoo Finance • 9 months ago

Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target

Investing.com - Stifel has reiterated its Buy rating and $21.00 price target on Lexeo Therapeutics (NASDAQ:LXEO), currently trading at $4.45, following the company’s announcement of Breakthrough Therapy Designation for its LX2006 treatme... Full story

Yahoo Finance • 9 months ago

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Con... Full story

Yahoo Finance • 10 months ago

Lexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting

Lexeo Therapeutics , Inc. (NASDAQ:LXEO) announced Monday that stockholders elected two Class II directors and ratified the selection of its independent registered public accounting firm during the company’s virtual 2025 Annual Meeting of S... Full story

Yahoo Finance • 10 months ago

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellect... Full story

Yahoo Finance • 10 months ago

Lexeo Therapeutics files to sell 41.63M shares of common stock for holders

* Lexeo Therapeutics (NASDAQ:LXEO [https://seekingalpha.com/symbol/LXEO]) filed to sell 41.63M shares of common stock for holders. * This prospectus is not an offer to sell. * Filing [https://seekingalpha.com/filing/10097725] MORE O... Full story

Yahoo Finance • 11 months ago

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participa... Full story

Yahoo Finance • last year

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional m... Full story